Literatur
-
1
Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O.
Pentoxifylline improves short-term survival in severe acute
alcoholic hepatitis: a double-blind, placebo-controlled
trial.
Gastroenterology.
2000;
119
1637-1648
-
2
Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, Amodio P, Sticca A, Caregaro L, Maffei-Faccioli A, Gatta A.
Reversal of type 1 hepatorenal syndrome with the
administration of midodrine and
octreotide.
Hepatology.
1999;
29
1690-1697
-
3
Arroyo V, Gines P, Gerbes A L, Dudley F, Gentilini P, Laffi G, Reynolds T B, Ring-Larsen H, Schölmerich J.
Definition and diagnostic criteria of refractory ascites and
hepatorenal syndrome in
cirrhosis.
Hepatology.
1996;
23
164-176
-
4
Brensing K A, Textor J, Perz J, Schiedermaier P, Raab P, Strunk H, Klehr H U, Kramer H J, Spengler U, Schild H, Sauerbruch T.
Long term outcome after transjugular intrahepatic
portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal
syndrome: a phase II
study.
Gut.
2000;
47
288-295
-
5
Ginès A, Escorsell A, Ginès P. et al .
Incidence, predictive factors, and prognosis of the
hepatorenal syndrome in cirrhosis with
ascites.
Gastroenterology.
1993;
105
229-236
-
6
Gonwa T A, Klintmalm G B, Levy M, Jennings L S, Goldstein R M, Husberg B S.
Impact of pretransplant renal function on survival after
liver
transplantation.
Transplantation.
1995;
59
361-365
-
7
Gülberg V, Bilzer M, Gerbes A L.
Long-term therapy and retreatment of hepatorenal syndrome
type 1 with ornipressin and
dopamine.
Hepatology.
1999;
30
870-875
-
8
Gülberg V, Gerbes A L.
TIPS or Vasoconstrictors for the Treatment of Hepatorenal
Syndrome Type 1 - Effect on Survival?.
Z
Gastroenterol.
2002;
40
823-826
-
9
Heemann U, Treichel U, Loock J, Philipp T, Gerken G, Malago M, Klammt S, Loehr M, Liebe S, Mitzner S, Schmidt R, Stange J.
Albumin dialysis in cirrhosis with superimposed acute liver
injury: A prospective, controlled
study.
Hepatology.
2002;
36
949-958
-
10
Kamath P.
Is there life in
MARS?.
Hepatology.
2002;
36
1017-1019
-
11
Lenz K, Hörtnagl H, Druml W, Reither H, Schmid R, Schneeweiss B, Laggner A, Grimm G, Gerbes A L.
Ornipressin in the treatment of functional renal failure in
decompensated liver cirrhosis: Effects on renal hemodynamics and atrial
natriuretic
factor.
Gastroenterology.
1991;
101
1060-1067
-
12
Moreau R, Durand F, Poynard T. et al .
Terlipressin in patients with cirrhosis and type 1
hepatorenal syndrome: a retrospective multicenter
study.
Gastroenterology.
2002;
122
923-930
-
13
Schrier R W, Arroyo V, Bernardi M, Epstein M, Henriksen J H, Rodes J.
Peripheral arterial vasodilation hypothesis: a proposal for
the initiation of renal sodium and water retention in
cirrhosis.
Hepatology.
1988;
8
1151-1157
-
14
Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, Castells L, Vargas V, Soriano G, Guevara M, Gines P, Rodes J.
Effect of intravenous albumin on renal impairment and
mortality in patients with cirrhosis and spontaneous bacterial
peritonitis.
N Engl J
Med.
1999;
341
403-409
-
15
Uriz J, Ginès P, Cárdenas A, Sort P, Jiménez W, Salmerón J M, Bataller R, Mas A, Navasa M, Arroyo V, Rodés J.
Terlipressin plus albumin infusion: an effective and safe
therapy of hepatorenal syndrome.
J
Hepatol.
2000;
33
43-48
-
16
Wong F, Blendis L.
New challenge of hepatorenal syndrome: prevention and
treatment.
Hepatology.
2001;
34
1242-1251
Prof. Dr. A. L. Gerbes
Medizinische Klinik II, Klinikum der
Ludwig-Maximilians-Universität München-Großhadern
Marchioninistraße 15
81377 München
Fax: 089/70952392
eMail: gerbes@med2.med.uni-muenchen.de
